Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1988 1
1990 2
1991 1
1992 3
1993 2
1994 1
1995 2
1996 1
1997 1
1998 3
1999 1
2000 5
2001 3
2002 11
2003 8
2004 19
2005 18
2006 16
2007 14
2008 22
2009 22
2010 13
2011 11
2012 12
2013 9
2014 9
2015 6
2016 4
2017 8
2018 6
2019 14
2020 8
2021 18
2022 13
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Thirasastr P, et al. Among authors: heinrich mc. Cancers (Basel). 2024 Feb 23;16(5):904. doi: 10.3390/cancers16050904. Cancers (Basel). 2024. PMID: 38473266 Free PMC article.
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T, Falkenhorst J, Schulz T, Fletcher BS, Teuber A, Krzeciesa D, Klooster I, Lundberg M, Wilson L, Lategahn J, von Mehren M, Grunewald S, Tüns AI, Wardelmann E, Sicklick JK, Brahmi M, Serrano C, Schildhaus HU, Sievers S, Treckmann J, Heinrich MC, Raut CP, Ou WB, Marino-Enriquez A, George S, Rauh D, Fletcher JA, Bauer S. Mühlenberg T, et al. Among authors: heinrich mc. J Clin Oncol. 2024 Apr 20;42(12):1439-1449. doi: 10.1200/JCO.23.01197. Epub 2024 Feb 26. J Clin Oncol. 2024. PMID: 38408285
Novel trial designs for patients with gastrointestinal stromal tumor.
Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Serrano C, et al. Among authors: heinrich mc. ESMO Open. 2024 Jan;9(1):102218. doi: 10.1016/j.esmoop.2023.102218. Epub 2024 Jan 8. ESMO Open. 2024. PMID: 38194880 Free PMC article. No abstract available.
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Heinrich MC, et al. Nat Med. 2024 Feb;30(2):498-506. doi: 10.1038/s41591-023-02734-5. Epub 2024 Jan 5. Nat Med. 2024. PMID: 38182785 Free PMC article. Clinical Trial.
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
Heinrich MC, Zhang X, Jones RL, George S, Serrano C, Deng Y, Bauer S, Cai S, Wu X, Zhou Y, Tao K, Zheng Z, Zhang J, Cui Y, Cao H, Wang M, Hu J, Yang J, Li J, Shen L. Heinrich MC, et al. Clin Cancer Res. 2024 Feb 16;30(4):719-728. doi: 10.1158/1078-0432.CCR-23-1861. Clin Cancer Res. 2024. PMID: 38032349 Clinical Trial.
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.
Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Serrano C, et al. Among authors: heinrich mc. Nat Med. 2023 Nov;29(11):2689-2692. doi: 10.1038/s41591-023-02578-z. Nat Med. 2023. PMID: 37828359 No abstract available.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Gelderblom H, et al. Among authors: heinrich mc. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. Eur J Cancer. 2023. PMID: 37598656 Free article. Clinical Trial.
279 results